Topic

Articles

Some observations point to hope for an upturn.

Are We Closer Than Ever to a Biotech Bottom?

Living to fight another day, as potential investment spark looms.

Biotech Prospects for Stayin’ Alive During Correction

What will current stranglehold mean for industry down the line?

Surviving Biotech’s Longest and Steepest Bear Market Ever 

Genomic data is transforming precision medicine—but progress depends on it being easily available where it’s needed. Pharmaceutical Executive speaks to Ignacio Medina, founder of Cambridge University spinout Zetta Genomics, to see how next-generation open-source data technologies accelerate discovery in the lab and patient benefit in the clinic.

Q&A With Ignacio Medina, founder, Zetta Genomics

Full-year business review of pharma and biotech sectors reveals strong momentum in advancing novel science and treatments, but likely foretells continued stock instability in near-to-medium terms.

Biopharma in 2021: Big Gains, Volatile Values

But a doubling-down on R&D offers reason for optimism.

Biopharma Stocks, M&A Sputter Amid More Headwinds

Biopharma stock performance continues to struggle.

What’s Up in Biotech These Days? Not Much, Unfortunately

Brief summary of EY’s 2022 M&A Firepower report highlights trends.

Biopharma Reaches New Heights as Calendar Turns

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

Ahead of the release of EY’s annual M&A Firepower report this week, Pharm Exec talks to EY’s Arda Ural to review biopharma M&A activity in 2021 and to discuss the likely deal drivers of 2022.

Biopharma M&A Firepower: Current Trends and Outlook

Christopher J. Calhoun is Chairman & CEO of 

, a biotechnology company developing the world’s first autologous, device-based disease modifying cell therapy for chronic conditions into late (approval) stage clinical trials based on robust prior clinical data.

Christopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.

Finance